[Management of acute lymphoblastic leukemia].
Noriko
N
Usui
D015703:Antigens, CD / Q000032:analysis; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001549:Benzamides; D015415:Biomarkers / Q000032:analysis; D003131:Combined Modality Therapy; D000069439:Dasatinib; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D000068877:Imatinib Mesylate; D025202:Molecular Diagnostic Techniques; D010879:Piperazines / Q000627:therapeutic use; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000175:diagnosis* / Q000453:epidemiology / Q000503:physiopathology / Q000628:therapy*; D011743:Pyrimidines / Q000627:therapeutic use; D012074:Remission Induction; D013844:Thiazoles / Q000627:therapeutic use
D015703:Antigens, CD; D001549:Benzamides; D015415:Biomarkers; D010879:Piperazines; D011743:Pyrimidines; D013844:Thiazoles; D000068877:Imatinib Mesylate; D000069439:Dasatinib